Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 phase IIb trial in grass pollen allergy
NL-OMON39223Phase 2Active, not recruiting
- Sponsor
- Biomay AG
- Start
- Jul 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BM32 in grass pollen allergy and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Biomay AG. Started Jul 2012; status: active, not recruiting.
02
Drugs
BM32
03
Conditions
grass pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON39223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39223.